Danaher Co. (NYSE:DHR) Shares Bought by Peloton Wealth Strategists

Peloton Wealth Strategists raised its position in shares of Danaher Co. (NYSE:DHR) by 3.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,696 shares of the conglomerate’s stock after buying an additional 190 shares during the quarter. Peloton Wealth Strategists’ holdings in Danaher were worth $1,308,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Heck Capital Advisors LLC purchased a new stake in Danaher during the fourth quarter valued at about $27,000. Decker Retirement Planning Inc. purchased a new stake in Danaher during the fourth quarter valued at about $31,000. Golden State Wealth Management LLC purchased a new stake in Danaher during the fourth quarter valued at about $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in Danaher during the third quarter valued at about $39,000. Finally, MidAtlantic Capital Management Inc. purchased a new stake in Danaher during the third quarter valued at about $40,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on DHR shares. Jefferies Financial Group reduced their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target for the company in a research report on Friday, December 13th. The Goldman Sachs Group set a $250.00 price target on shares of Danaher in a research report on Wednesday, January 15th. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a research report on Thursday, October 31st. Finally, Wells Fargo & Company reduced their price target on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Seven research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Trading Down 1.8 %

NYSE:DHR opened at $205.69 on Friday. Danaher Co. has a 12 month low of $196.80 and a 12 month high of $281.70. The firm has a market cap of $147.01 billion, a price-to-earnings ratio of 38.96, a P/E/G ratio of 2.66 and a beta of 0.83. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The company’s 50 day moving average is $225.00 and its 200-day moving average is $245.50.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the business earned $2.09 EPS. Equities analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.32 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. This represents a $1.28 annualized dividend and a dividend yield of 0.62%. Danaher’s dividend payout ratio (DPR) is presently 24.24%.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 11.10% of the stock is currently owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.